Search results
Results from the WOW.Com Content Network
Erenumab, sold under the brand name Aimovig, is a medication which blocks the calcitonin gene-related peptide receptor (CGRPR) for the prevention of migraine. [ 3 ] [ 4 ] [ 5 ] It is administered by subcutaneous injection .
One theory to explain antidepressant-related weight gain is that psychotropic medications such as antidepressants can affect neurotransmitters involved in eating behavior, causing an increase in ...
The typical adult gains an average of 1 to 2 pounds per year, which over time, can contribute to obesity. This weight gain can be driven by physical inactivity, stress, poor sleep and poor food ...
The Food and Drug Administration approved on Thursday the first drug designed to prevent migraines. A once-monthly, self-injection, Aimovig is the first in a new class of long-acting drugs that is ...
Certain medications may cause weight gain or changes in body composition; these include insulin, sulfonylureas, thiazolidinediones, atypical antipsychotics, antidepressants, steroids, certain anticonvulsants (phenytoin and valproate), pizotifen, and some forms of hormonal contraception. [2]
Setmelanotide is an agonist of the melanocortin 4 receptor and is used in people with certain rare genetic conditions that cause obesity. It is less effective and not approved for general obesity. [16] Some weight loss drugs act on the neurotransmitters serotonin, dopamine, and norepinephrine to reduce appetite. [17]
“Clinicians and patients can use this information, among other factors, to help decide on the right choice for them,” he added. Greatest risk of at least 5% weight gain at six months of use ...
Overeating occurs when an individual consumes more calories in relation to the energy that is expended via physical activity or expelled via excretion, leading to weight gain and often obesity. Overeating is the defining characteristic of binge eating disorder. [1] Overeating can be a symptom of binge eating disorder or bulimia nervosa. [2] [1]